Literature DB >> 26414702

Altered Hypoxic-Adenosine Axis and Metabolism in Group III Pulmonary Hypertension.

Luis J Garcia-Morales1,2, Ning-Yuan Chen1, Tingting Weng1, Fayong Luo1, Jonathan Davies3, Kemly Philip1, Kelly A Volcik1, Ernestina Melicoff1, Javier Amione-Guerra2, Raquel R Bunge2, Brian A Bruckner2, Matthias Loebe2, Holger K Eltzschig4, Lavannya M Pandit5, Michael R Blackburn1, Harry Karmouty-Quintana1.   

Abstract

Group III pulmonary hypertension (PH) is a highly prevalent and deadly lung disorder with limited treatment options other than transplantation. Group III PH affects patients with ongoing chronic lung injury, such as idiopathic pulmonary fibrosis (IPF). Between 30 and 40% of patients with IPF are diagnosed with PH. The diagnosis of PH has devastating consequences to these patients, leading to increased morbidity and mortality, yet the molecular mechanisms involved in the development of PH in patients with chronic lung disease remain elusive. Our hypothesis was that the hypoxic-adenosinergic system is enhanced in patients with group III PH compared with patients with IPF with no PH. Explanted lung tissue was analyzed for markers of the hypoxic-adenosine axis, including expression levels of hypoxia-inducible factor (HIF)-1A, adenosine A2B receptor, CD73, and equilibrative nucleotide transporter-1. In addition, we assessed whether altered mitochondrial metabolism was present in these samples. Increased expression of HIF-1A was observed in tissues from patients with group III PH. These changes were consistent with increased evidence of adenosine accumulation in group III PH. A novel observation of our study was of evidence suggesting altered mitochondrial metabolism in lung tissue from group III PH leading to increased succinate levels that are able to further stabilize HIF-1A. Our data demonstrate that the hypoxic-adenosine axis is up-regulated in group III PH and that subsequent succinate accumulation may play a part in the development of group III PH.

Entities:  

Keywords:  adenosine A2B receptor; group III pulmonary hypertension; hypoxia-inducible factor-1A; idiopathic pulmonary fibrosis; succinate

Mesh:

Substances:

Year:  2016        PMID: 26414702      PMCID: PMC4821053          DOI: 10.1165/rcmb.2015-0145OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  41 in total

Review 1.  HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations.

Authors:  Gregg L Semenza
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

Review 2.  World Health Organization Group III pulmonary hypertension.

Authors:  Hooman D Poor; Reda Girgis; Sean M Studer
Journal:  Prog Cardiovasc Dis       Date:  2012 Sep-Oct       Impact factor: 8.194

Review 3.  PGC1α and mitochondrial metabolism--emerging concepts and relevance in ageing and neurodegenerative disorders.

Authors:  Shane Austin; Julie St-Pierre
Journal:  J Cell Sci       Date:  2012-11-01       Impact factor: 5.285

Review 4.  Idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Annie Pardo; Moisés Selman
Journal:  Lancet       Date:  2011-06-28       Impact factor: 79.321

5.  Adenosine A2B receptor and hyaluronan modulate pulmonary hypertension associated with chronic obstructive pulmonary disease.

Authors:  Harry Karmouty-Quintana; Tingting Weng; Luis J Garcia-Morales; Ning-Yuan Chen; Mesias Pedroza; Hongyan Zhong; Jose G Molina; Raquel Bunge; Brian A Bruckner; Yang Xia; Richard A Johnston; Matthias Loebe; Dewan Zeng; Harish Seethamraju; Luiz Belardinelli; Michael R Blackburn
Journal:  Am J Respir Cell Mol Biol       Date:  2013-12       Impact factor: 6.914

6.  PGC1α-mediated mitofusin-2 deficiency in female rats and humans with pulmonary arterial hypertension.

Authors:  John J Ryan; Glenn Marsboom; Yong-Hu Fang; Peter T Toth; Erik Morrow; Nancy Luo; Lin Piao; Zhigang Hong; Kyle Ericson; Hannah J Zhang; Mei Han; Chad R Haney; Chin-Tu Chen; Willard W Sharp; Stephen L Archer
Journal:  Am J Respir Crit Care Med       Date:  2013-04-15       Impact factor: 21.405

Review 7.  Adenosine signaling during acute and chronic disease states.

Authors:  Harry Karmouty-Quintana; Yang Xia; Michael R Blackburn
Journal:  J Mol Med (Berl)       Date:  2013-01-23       Impact factor: 4.599

8.  Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.

Authors:  Peppi Koivunen; Sungwoo Lee; Christopher G Duncan; Giselle Lopez; Gang Lu; Shakti Ramkissoon; Julie A Losman; Päivi Joensuu; Ulrich Bergmann; Stefan Gross; Jeremy Travins; Samuel Weiss; Ryan Looper; Keith L Ligon; Roel G W Verhaak; Hai Yan; William G Kaelin
Journal:  Nature       Date:  2012-02-15       Impact factor: 49.962

9.  Increased CD39 nucleotidase activity on microparticles from patients with idiopathic pulmonary arterial hypertension.

Authors:  Scott H Visovatti; Matthew C Hyman; Diane Bouis; Richard Neubig; Vallerie V McLaughlin; David J Pinsky
Journal:  PLoS One       Date:  2012-07-11       Impact factor: 3.240

10.  HIF1A reduces acute lung injury by optimizing carbohydrate metabolism in the alveolar epithelium.

Authors:  Tobias Eckle; Kelley Brodsky; Megan Bonney; Thomas Packard; Jun Han; Christoph H Borchers; Thomas J Mariani; Douglas J Kominsky; Michel Mittelbronn; Holger K Eltzschig
Journal:  PLoS Biol       Date:  2013-09-24       Impact factor: 8.029

View more
  19 in total

1.  Glutamine metabolism drives succinate accumulation in plasma and the lung during hemorrhagic shock.

Authors:  Anne L Slaughter; Angelo D'Alessandro; Ernest E Moore; Anirban Banerjee; Christopher C Silliman; Kirk C Hansen; Julie A Reisz; Miguel Fragoso; Matthew J Wither; Anthony W Bacon; Hunter B Moore; Erik D Peltz
Journal:  J Trauma Acute Care Surg       Date:  2016-12       Impact factor: 3.313

Review 2.  Hypoxia-inducible factor signaling in pulmonary hypertension.

Authors:  Soni Savai Pullamsetti; Argen Mamazhakypov; Norbert Weissmann; Werner Seeger; Rajkumar Savai
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

Review 3.  Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin?

Authors:  Farhanah Yousaf; Bruce Spinowitz
Journal:  Curr Hypertens Rep       Date:  2016-03       Impact factor: 5.369

Review 4.  Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra.

Authors:  Keshava Rajagopal; Andrew J Bryant; Sandeep Sahay; Nancy Wareing; Yang Zhou; Lavannya M Pandit; Harry Karmouty-Quintana
Journal:  Br J Pharmacol       Date:  2020-04-07       Impact factor: 8.739

5.  Biochemical, biophysical, and immunological characterization of respiratory secretions in severe SARS-CoV-2 infections.

Authors:  Michael J Kratochvil; Gernot Kaber; Sally Demirdjian; Pamela C Cai; Elizabeth B Burgener; Nadine Nagy; Graham L Barlow; Medeea Popescu; Mark R Nicolls; Michael G Ozawa; Donald P Regula; Ana E Pacheco-Navarro; Samuel Yang; Vinicio A de Jesus Perez; Harry Karmouty-Quintana; Andrew M Peters; Bihong Zhao; Maximilian L Buja; Pamela Y Johnson; Robert B Vernon; Thomas N Wight; Carlos E Milla; Angela J Rogers; Andrew J Spakowitz; Sarah C Heilshorn; Paul L Bollyky
Journal:  JCI Insight       Date:  2022-06-22

6.  Macrophage bone morphogenic protein receptor 2 depletion in idiopathic pulmonary fibrosis and Group III pulmonary hypertension.

Authors:  Ning-Yuan Chen; Scott D Collum; Fayong Luo; Tingting Weng; Thuy-Trahn Le; Adriana M Hernandez; Kemly Philip; Jose G Molina; Luis J Garcia-Morales; Yanna Cao; Tien C Ko; Javier Amione-Guerra; Odeaa Al-Jabbari; Raquel R Bunge; Keith Youker; Brian A Bruckner; Rizwan Hamid; Jonathan Davies; Neeraj Sinha; Harry Karmouty-Quintana
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-06-17       Impact factor: 5.464

7.  Inhibition of hyaluronan synthesis attenuates pulmonary hypertension associated with lung fibrosis.

Authors:  Scott D Collum; Ning-Yuan Chen; Adriana M Hernandez; Ankit Hanmandlu; Heather Sweeney; Tinne C J Mertens; Tingting Weng; Fayong Luo; Jose G Molina; Jonathan Davies; Ian P Horan; Nick W Morrell; Javier Amione-Guerra; Odeaa Al-Jabbari; Keith Youker; Wenchao Sun; Jayakumar Rajadas; Paul L Bollyky; Bindu H Akkanti; Soma Jyothula; Neeraj Sinha; Ashrith Guha; Harry Karmouty-Quintana
Journal:  Br J Pharmacol       Date:  2017-08-17       Impact factor: 8.739

8.  Calpain-1 mediates vascular remodelling and fibrosis via HIF-1α in hypoxia-induced pulmonary hypertension.

Authors:  Haiyan Deng; Xiaoxue Tian; Hening Sun; Huan Liu; Meili Lu; Hongxin Wang
Journal:  J Cell Mol Med       Date:  2022-04-01       Impact factor: 5.295

Review 9.  Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension.

Authors:  Allan K N Alencar; Guilherme C Montes; Eliezer J Barreiro; Roberto T Sudo; Gisele Zapata-Sudo
Journal:  Front Pharmacol       Date:  2017-12-04       Impact factor: 5.810

10.  Transcriptomic and Epigenetic Profiling of Fibroblasts in Idiopathic Pulmonary Fibrosis.

Authors:  Ankit Hanmandlu; Lisha Zhu; Tinne C J Mertens; Scott Collum; Weizhen Bi; Feng Xiong; Ruoyu Wang; Rajarajan T Amirthalingam; Dewei Ren; Leng Han; Soma S S K Jyothula; Wenbo Li; W Jim Zheng; Harry Karmouty-Quintana
Journal:  Am J Respir Cell Mol Biol       Date:  2022-01       Impact factor: 7.748

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.